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Abstract
Background: Despite the improvements in diagnosis and treatment, colorectal cancer (CRC) is the second cause of
cancer deaths in both sexes. Therefore, research in this field remains of great interest. The approval of bevacizumab,
a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with a
fluoropyrimidine-based chemotherapy in the treatment of metastatic CRC has changed the oncology practice in
this disease. However, the efficacy of bevacizumab-based treatment, has thus far been rather modest. Efforts are
ongoing to understand the better way to combine bevacizumab and chemotherapy, and to identify valid
predictive biomarkers of benefit to avoid unnecessary and costly therapy to nonresponder patients. The BRANCH
study in high-risk locally advanced rectal cancer patients showed that varying bevacizumab schedule may impact
on the feasibility and efficacy of chemo-radiotherapy.
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Methods/Design: OBELICS is a multicentre, open-label, randomised phase 3 trial comparing in mCRC patients two
treatment arms (1:1): standard concomitant administration of bevacizumab with chemotherapy (mFOLFOX/OXXEL
regimen) vs experimental sequential bevacizumab given 4 days before chemotherapy, as first or second treatment
line. Primary end point is the objective response rate (ORR) measured according to RECIST criteria. A sample size of
230 patients was calculated allowing reliable assessment in all plausible first-second line case-mix conditions, with a
80 % statistical power and 2-sided alpha error of 0.05. Secondary endpoints are progression free-survival (PFS),
overall survival (OS), toxicity and quality of life. The evaluation of the potential predictive role of several circulating
biomarkers (circulating endothelial cells and progenitors, VEGF and VEGF-R SNPs, cytokines, microRNAs, free
circulating DNA) as well as the value of the early [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET)
response, are the objectives of the traslational project.
Discussion: Overall this study could optimize bevacizumab scheduling in combination with chemotherapy in
mCRC patients. Moreover, correlative studies could improve the knowledge of the mechanisms by which
bevacizumab enhance chemotherapy effect and could identify early predictors of response.
EudraCT Number: 2011-004997-27
Trial registration: ClinicalTrials.gove number, NCT01718873
Keywords: Colorectal cancer, Bevacizumab, Oxaliplatin, Vessel normalization, FDG-PET, Biomarkers for anti-angiogenic
therapy
Background
Bevacizumab in the treatment of colorectal cancer
Colorectal cancer (CRC) is the second most common
cancer and the third cause of cancer deaths in both
sexes, comprising approximately 13 % of all new cancer
diagnoses in Europe [1]. Approximately, 15 % of patients
with CRC are diagnosed with metastatic disease, and a
further 40–50 % will develop metastases during the
course of their disease. Despite the improvements in
diagnosis and treatment, unresectable metastatic colo-
rectal cancer (mCRC) remains an incurable disease with
a 5-year survival rate of approximately 10 % [1]. There-
fore, research in this field remains of great interest. In
the last ten years angiogenesis has emerged as a crucial
hallmark of cancer development, becoming a key target
for cancer treatment [2, 3]. Tumor angiogenesis is char-
acterized by structural and functional abnormalities of
vasculature with a relatively inefficient blood supply and
the vascular endothelial growth factor (VEGF) has a
crucial role in these abnormalities [4, 5]. Bevacizumab, a
humanized monoclonal antibody that inhibits tumor
angiogenesis by blocking VEGF, has been the first anti-
angiogenic agent approved for the treatment of cancer.
Its approval in combination with a fluoropyrimidine-
based chemotherapy has changed oncology practice of
mCRC. However, despite promising preclinical results,
the objective response rates (ORR) and survival benefits
of bevacizumab have thus far been rather limited, stimu-
lating interest in developing more effective ways to
combine the drug and the chemotherapy [6]. Moreover,
the magnitude of the benefit is heterogeneous across
trials and seems to be affected by the chemotherapeutic
regimen with which bevacizumab is partnered. In the
NO16966 trial, bevacizumab in combination with
XELOX or FOLFOX-4 in the first line treatment of pa-
tients with mCRC, did not increase the ORR (38 % vs
38 %), did not significantly prolong the overall survival
(OS) and, although the progression-free survival (PFS)
was significantly improved (HR = 0,83; P = 0.0023), the
improvement was clinically modest (only 1,4 months)
and markedly less than that found in the AVF2107 trial,
where the drug was combined with IFL [7, 8]. The mod-
est benefit in survival observed in the NO16966 trial
might be explained by the fact that the majority of pa-
tients did not continue the treatment until progression,
however the lack of impact of bevacizumab on RR would
remain unclear [7].
Other two randomized phase 3 trials confirmed that
bevacizumab combined with first-line chemotherapy is
not superior to chemotherapy alone [9, 10].
Overall, these data suggest that additional investigation
are needed to improve bevacizumab antitumor effect
and to identify valid predictive biomarkers for patient
selection [11].
Mechanism of action of bevacizumab
Despite extensive preclinical and clinical studies little is
known about the mechanism (or mechanisms) of action
of bevacizumab, especially when co-administered with
chemotherapy. Emerging data suggest that bevacizumab,
not only blocks the growth of new blood vessels [12],
but also induces pharmacodynamic changes that support
the “vessel normalization” hypothesis [4, 13]. As the ab-
normal tumor vasculature produces elevated interstitial
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fluid pressure, tumor hypoxia and reduces blood flow
and perfusion, this prevents the delivery of anticancer
drugs and may cause resistance to chemotherapy [4].
The treatment with bevacizumab can normalize the
tumor vasculature, resulting in more efficient drug and
oxygen delivery to cancer cells [4, 14]. However, this
process of vascular normalization seems to be transient
and with a relatively narrow therapeutic window. Chemo-
therapy and/or radiation therapy given during this tran-
sient “window of normalization” may be more effective
[4, 15–17]. Preclinical eivdences suggest that bevacizu-
mab needs at least 4–5 days to reduce tumor interstitial
fluid pressure and increase tumor oxygenation [15–17].
In this scenario, the optimal scheduling of the anti-
angiogenic agent with the cytotoxic therapies would
become the major determinant of the overall thera-
peutic effect.
Rationale
Critical role of bevacizumab scheduling in combination
with pre-surgical chemo-radiotherapy in locally advanced
rectal cancer: the BRANCH study
Based on the “vessels normalization” hypothesis, we
performed a non-randomized, non-comparative phase 2
study to assess the safety and the activity of a traditional
concurrent and an experimental sequential (4 days before
chemo-radiotherapy) administration of bevacizumab, with
preoperative chemo-radiotherapy, in magnetic resonance
imaging (MRI)-defined high-risk locally advanced rectal
cancer (LARC) patients (BRANCH study) [18]. Patients
received three biweekly cycles of pre-operative oxaliplatin
(OXA), raltitrexed (RTX), fluorouracil (5FU), and folinic
acid (LFA), during pelvic radiotherapy (RT). Bevacizumab
was given 2 weeks before the start of chemo-RT and on
the same day of chemotherapy for three cycles (concomi-
tant-schedule) or 4 days prior to the first and second cycle
of chemotherapy (sequential-schedule). The primary end
point was pathological complete tumor regression (TRG1)
rate. To establish the sample size, the Simon’s two-stage
design was applied. Setting α and β errors at 0.05 and
0.20, respectively, and defining as the minimum activity of
interest (p0) a TRG1 rate of 30 %, in order to accept the
alternative hypothesis (p1) of a TRG1 rate ≥ 50 %, at least
6 TRG1 in the first 15 patients and at least 19 TRG1
among a total of 46 patients would need to be reported in
the first and second stage, respectively. The accrual in the
concomitant-schedule group was early stopped due to lack
of activity (two TRG1 out of 16 patients). Conversely, a
TRG1 rate of 50 % (95 % CI 35–65 %) was obtained with
the sequential-schedule among the 46 enrolled patients.
In this group, the 5-year probability of progression free-
survival (PFS) and OS were 80 % (95 % CI 66–89 %) and
85 % (95 % CI 69–93 %), respectively. Neutropenia was
the most common grade ≥3 toxicity with both schedules,
but it was less frequent with the sequential than the
concomitant-schedule (30 % vs. 44 %). Such result
have been recently confirmed by data from preclinical
studies, showing that the sequential delivery of an
anti-angiogenic therapy followed by chemotherapy in-
duces less bone marrow toxicity than concomitant ad-
ministration [19].
These results highlight the relevance of bevacizumab
scheduling to optimize its combination with chemo-RT.
Circulating biomarkers and imaging study
The identitification of validated predictive biomarkers of
anti-angiogenic therapy efficacy remains an unmeet
need. Recent studies suggested that bevacizumab could
induce a chemosensitization also inhibiting the rapid
tumor cell repopulation that can take place between suc-
cessive chemotherapy administrations [20]. Such process
involves several cytokines and the mobilitation of the
circulating endothelial cells (CEC) and endothelial pro-
genitor cells (EPC), which are rare cell subsets, detect-
able in peripheral blood, cord blood and bone marrow
that act as key players in the maintenance of the endothe-
lial homeostasis. CEC, characterized by mature endothelial
features, detach from vessel walls, following vascular dam-
age or its physiological turnover, and become circulating
cells [21]. On the other hand, EPC, characterized by an
immature phenotype, are bone marrow-resident cells, mo-
bilized upon specific stimulation, including chemotherapy,
that, once in the bloodstream, are involved in the endo-
thelial repair or remodeling [20, 22]. Over the past decade,
several reports demonstrated a high CECs count in the
peripheral blood of cancer patients at diagnosis; therefore,
it might be a promising tool for patients who would bene-
fit from anti-angiogenic therapies [21, 23, 24]. On the
other hand, chemotherapy can mobilized EPCs from bone
marrow that may contribute to neovascularization; there-
fore, an early anti-angiogenic therapy in combination with
chemotherapy could enhance treatment effect [20, 25].
Functional analyses of early clinical study in LARC pa-
tients have confirmed that bevacizumab normalizes tumor
vasculature and decreases CECs and EPCs count [26, 27].
A recent study confirmed a host response with EPC
mobilization in colorectal cancer patients during FOLFOX
adjuvant chemotherapy, which resulted significantly inhib-
ited by the addition of bevacizumab to FOLFOX [28].
Interestingly, in the BRANCH study we showed that base-
line CEC counts were higher in responding (TRG1-2) vs
non-responding (TRG3-4) patients and that CEC counts
significantly reduced during treatment only in the respon-
ders [29].
Although different flow cytometry methods for CEC
and EPC characterization have been published so far, no
one has reached consistent conclusions. Therefore consen-
sus guidelines with respect to CEC and EPC identification
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and quantification need to be established. On this regard,
we have been recently involved in a multicentre study car-
rying out a deep investigation of CEC and EPC phenotypes
and optimizing a simple and reliable polychromatic flow
cytometry single panel method that allows the assessment
of these cellular populations in the perypheral blood of
healthy donors. Interestingly, our data also suggest that the
antigen profile for the identification of endothelial progeni-
tors circulating in the bloodstream might be redefined [30].
Some recent reports have evidenced that several circu-
lating cytokines might be modulated in cancer patients
undergoing anti-VEGF therapy, correlating with antitumor
efficacy [31, 32]. On this regard, multiplex technologies
offer a noninvasive, easy and convenient method of
simultaneously assessing a large number of biologic-
ally relevant citochine and angiogenic factor from small
plasma volumes.
It has been recently demonstrated that single nucleotide
polymorphisms (SNP) in VEGF, VEGF-R and other genes
involved in angiogenesis, alter their proteins concentrations
influencing the process of angiogenesis. Moreover, VEGF
SNPs seems to play an important role in the risk of recur-
rence, prognosis and survival of colorectal cancer as well as
in the response to bevacizumab treatment [11, 33–35].
The high stability of circulating free DNA (cfDNA)
and miRNA in the plasma of patients with cancer,
suggest the possibility to identify innovative predictive
biomarkers of benefit or resistance for anti-angiogenic
therapy. Blood-based molecular tests, such as the so-
called “liquid biopsy”, can be used to detect cancer-
specific DNA alterations in plasma of colorectal cancer
patients with very high sensitivity and might be applied
for monitoring treatment response and assessing min-
imal residual disease [36]. Moreover, recent studies have
shown that the expression of microRNAs (miRNAs) in
the plasma of patients with colorectal cancer could be
used for diagnosis and prognosis [37]. MiRNAs may also
mediate the regulation of “switch” angiogenesis [38].
There are also experimental evidence demonstrating a
possible use of miRNA expression for the prediction of
response to various chemotherapy [39].
Our group has previously reported that early metabolic
change evaluated by [18F]-Fluorodeoxyglucose positron
emission tomography (FDG-PET) is able to predict pa-
thologic tumor response and outcome in rectal cancer
[40, 41] and in mCRC [42]. Interestingly, in the BRANCH
study we have also observed a greater early reduction
(11 days after chemo-RT) of median tumor metabolic vol-
ume, evaluated by FDG-PET in the sequential-schedule
than in the concomitant-schedule [43].
Methods/Design
OBELICS is a prospective, multicentre, open-label, ran-
domised, phase 3 trial evaluating the optimization of
bevacizumab scheduling in combination with chemother-
apy in mCRC patients. The study includes an explorative
analysis of the potential prognostic or predictive role of
several circulating biomarkers as well as of early FDG-
PET evaluation. With the aim of improving the knowledge
of the mechanisms by which bevacizumab enhances
chemotherapy effect and of identifying early predictors of
treatment response/resistence.
Objectives
The primary objective of the study is to assess whether an
experimental schedule of bevacizumab, given sequentially
instead of concomitantly with oxaliplatin regimen (mFOL-
FOX/mOXXEL), can improve treatment activity (in terms
of objective response rate) in patients with mCRC.
Secondary objectives are to evaluate the impact of the
experimental schedule on PFS, OS, toxicity and quality
of life.
Moreover, the study has the objective of validating the
prognostic and predictive role of the early metabolic
response evaluated by FDG-PET (11 days after the start
of the first cycle of chemotherapy in both arms, that is
15 days after the first administration of bevacizumab in
the experimental arm).
Exploratory secondary objective is to evaluate the
prognostic and predictive value of: a) CEC and EPC
counts on patient blood samples at baseline and at dif-
ferent time points during and after treatment; b) cyto-
kine and circulating angiogenic factors plasma levels on
patient blood samples at baseline and at different time
points during and after treatment; c) miRNAs on patient
blood samples at baseline and at different time points
during and after treatment; d) single nucleotide polymor-
phisms (SNPs) of VEGF and VEGF receptor (VEGF-R) on
patient blood samples; e) white blood cells counts at 24 h
after the first administration of bevacizumab on patient
blood samples; f ) genetic alterations on tumor tissues
and/or on cfDNA.
Ethical aspects
The procedures set out in this study protocol are de-
signed to ensure that the principles of the Good Clinical
Practice guidelines of the International Conference on
Harmonization (ICH) and the Declaration of Helsinki
are respected in the conduct, evaluation and documenta-
tion of this study. The study was approved by the Ethical
Committee of the National Cancer Institute of Naples,
Italy. Patients provide written informed consent for par-
ticipating in the study and for allowing to collect tissue
and blood samples.
Study design
OBELICS is a two-arm phase 3 trial comparing in
mCRC patients (1:1): concurrent administration of
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bevacizumab in combination with modified FOLFOX-6
regimen (mFOLFOX-6) or modified OXXEL regimen
(mOXXEL), in which bevacizumab is administered the
same day as oxaliplatin, (standard arm); and sequential
administration of bevacizumab with the same chemother-
apeutic regimens, in which bevacizumab is administered
4 days before oxaliplatin at each cycle (experimental arm)
(Fig. 1). Oxaliplatin regimen (mFOLFOX/mOXXEL) is
chosen according to local clinical practice at the beginning
of the study.
In both arms, the patients not progressing after 12 cy-
cles (24 weeks) of treatment, stop chemotherapy and
continue maintenance bevacizumab (7.5 mg/kg every
3 weeks) until progression, unacceptable toxicity or pa-
tient’s choice to stop.
Primary end point is objective ORR according to
RECIST criteria version 1.1.
Study sample size is defined according to the ORR
expected in the control arm; it varies as a function of
the proportion of patients in first and in second line of
treatment enrolled in the study. Assuming 40 % as the
expected first line ORR and 20 % as the expected second
line one, the sample size is calculated within three differ-
ent expected ORR: 35 % (75 % as first line and 25 % as
second line), 30 % (50 and 50 % respectively) and 25 %
(25 and 75 % respectively). In the Table 1, the expected
sample size is reported, under the three hypothesized
conditions, fixing an odds ratio of 2.25, 80 % statistical
power and 2-sided alpha error of 0.05. We have also re-
ported the auspicated ORRs, in the experimental arm,
and the corresponding relative risks, ranging from 1.6 to
1.7. As expected, odds ratio represents an overestimation
of relative risk, and the extent of overestimation increases
with increasing the expected ORR. Therefore, a sample
size of 220–230 patients will allow reliable assessment in
all plausible case-mix conditions.
Patient selction criteria
Inclusion criteria
Patients are eligible if ≥18 and ≤ 75 years old, diagnosed
with metastatic adenocarcinoma of colon or rectum
(Stage IV), regardless of RAS mutational status, have at
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Fig. 1 Schematic timeline of study procedures
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least one measurable target lesion (according to the
RECIST criteria), have an ECOG Performance Status ≤1
at study entry and a life expectancy > 3 months. More-
over, they have to had adequately recovered from recent
surgery (at least 28 days after a major surgery or biopsy)
and consenting to use effective contraception if the risk
of conception exist. All the patients sign a written in-
formed consent.
Exclusion criteria
Patients are excluded if they have received more than one
line of treatment for metastatic disease, or a previous
treatment with bevacizumab or oxaliplatin (a previous
treatment with fluoropirymidines, folic acid, irinotecan or
cetuximab is allowed); have a primary cancer that pro-
duces stenosis or full-thickness wall infiltration not re-
solved by stent placement or surgery; use regularly
NSAID or aspirin (more than 325 mg/die) or anticoagu-
lants at therapeutic dose; have bleeding diathesis or pre-
existing coagulopathy; have known or suspected brain
metastases (determined exclusively in the presence of at
least one clinical symptom); have inadequate bone mar-
row, liver or renal function (Neutrophils < 2000/mm3 or
platelets < 100.000/mm3 or haemoglobin <9 gr/dl; creatin-
ine levels of >1.5 time the upper normal limit UNL; GOT
and/or GPT > 2.5 time the UNL and/or bilirubin >1.5 time
the UNL in absence of liver metastasis; GOT and/or
GPT > 5 time the UNL and/or bilirubin > 3 time the UNL
in presence of liver metastasis; have had any other malig-
nancy other than non-melanomatous skin cancer, or car-
cinoma in situ of the cervix In the last 5 years; have
congestive heart failure, recent ischemic coronary disease
(last 12 months), uncontrolled arrhythmia, uncontrolled
hypertension, active or uncontrolled infection, or any
other serious uncontrolled medical disorder that in the
opinion of the investigator would impair the ability of the
subject to receive protocol therapy. Pregnant or lactating
women are excluded. Moreover, patients with a history or
current evidence on physical examination of central ner-
vous system disease or peripheral neuropathy > grade 1
(CTCAE v. 4.0), or are unable to comply with follow-up
are excluded.
Treatment plan
In the standard arm bevacizumab (5 mg/kg) is administered
as 20- to-30 min intravenous infusion before oxaliplatin on
day 1 of each cycle of mFOLFOX-6 regimen (oxaliplatin
85 mg/m2 i.v. infusion on day 1 followed by levo-folinic
acid 200 mg/m2 i.v. infusion followed by i.v. bolus 5-
fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-
fluorouracil 2400 mg/m2) or mOXXEL regimen (oxalipla-
tin 85 mg/m2 i.v. infusion on day 1 plus oral capecitabine
1000 mg/m2 twice daily on days 1 to 10) every
2 weeks for 12 cycles (24 weeks). In the experimental
arm bevacizumab (5 mg/kg) is administered 4 days
(day −4) before oxaliplatin on day 1 of each cycle of
mFOLFOX-6 or mOXXEL regimen (at same doses
used in the standard arm) every 2 weeks for 12 cycles
(24 weeks) (Fig. 1).
Thereafter, in both arms, patients who are progression
free after 12 cycles (24 weeks) of treatment continue
maintenance bevacizumab (7.5 mg/kg every 3 weeks) ±
fluoropyrimidines until disease progression or unaccept-
able toxicity.
Surgery may be carried out in case of appropriate
tumour reduction is evident at response evaluation.
Resectability has to be evaluated by a multidisciplinary
review team and the decision regarding post-surgery
chemotherapy is at the discretion of the investigators,
according to their local clinical practice.
In cases of prespecified adverse events, treatment
modifications are permitted as follow: a 25 % fluoropyri-
midines dose reduction is applied in subsequent cycles in
case of grade ≥ 3 of haematologic or non-haematologic
toxicities (except for alopecia); at the second appearance
of these side effects a dose reduction of 50 % of fluoropyri-
midines may be applied; after a further grade ≥ 3 toxicity
or after the first appearance of grade ≥ 3 sensory neur-
opathy, a 25 % oxaliplatin dose reduction is planned; at
the second appearence of grade ≥ 3 sensory neuropathy a
50 % oxaliplatin dose reduction is also planned; otherwise
chemotherapy is permanently discontinued. No profilactic
use of G-CSF or eritropoyetin is planned. No dose-
reduction is planned for bevacizumab.
Bevacizumab has to be permanently discontinued in
patients who develop any one of the following toxicities:
gastrointestinal perforation, grade ≥ 3 thromboembolism,
grade 4 hemorrhage, grade ≥ 3 hypertension or proteinuria,
congestive heart failure.
An anti-hypertensive treatment (ACE inhibitors and/or
calcium antagonists at standard doses) should be under-
taken in case of grade ≥ 2 hypertension (recurrent or per-
sistent), or in case of an increase symptomatic > 20 mmHg
(diastolic) or in case of a pressure > 150/100 mm Hg if
normal at baseline.
Assessment and procedures
Assessment and procedures, including those for
exploratory objectives (see below) are illustrated in
Fig. 1.
Table 1 Plausible case mix conditions
% expected
response in
standard arm
# patients % expected
response in
experimental arm
Relative risk
(experimental
vs standard)
35 201 54,8 % 1,57
30 209 49,1 % 1,63
25 230 42,9 % 1,71
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Toxicity evaluation criteria
Toxicity is graded according to the Common Terminology
Criteria for Adverse Events (CTCAE) of the National
Cancer Institute, version 4.0, June 14, 2010.
Adverse events are assessed at the following times:
baseline (within 3 weeks before the treatment start),
weekly (blood count) and beweekly (biochemistry, phys-
ical examination, ECOG performance status and vital
signs including blood pressure) during the treatment.
ECG is performed at weeks 12 and 24 weeks from
randomization.
Response evaluation criteria
Response is assessed at week 12 and 24 from rando-
mization, and every 3 months thereafter, until disease pro-
gression, by repeating: CT scan of chest, abdomen and
pelvis; CEA, CA 19.9; any other tests having resulted
positive during baseline staging. Objective response will
be categorized according to Response Evaluation Criteria
in Solid Tumors (RECIST) v. 1.1. An independent
blinded central review of radiologic examinations will be
performed.
FDG-Positron Emission Tomography (PET) imaging
FDG PET-CT scans are planned at baseline (within
3 weeks before treatment start) and 11 days after the
start of the first cycle of chemotherapy in both arms
(that is 15 days after the first administration of bevacizu-
mab in the experimental arm).
Patients have to be fasted for at least 6 h and blood
glucose level have to be less than 150 mg/dL. FDG-PET
images are reconstructed using iterative reconstruction
and normalized for injected dose and patient body weight.
Image analysis is performed utilizing a semi-automatic
region-of-interest (ROI) drawing software package where
a three-dimensional region is drawn around the area of
increased uptake. Threshold values are adjusted in order
to encompass the area of increased uptake visually.
For each tumor volume, the following parametres are
calculated: a) SUV = (measured activity concentration
[Bq/mL])/(injected activity [Bq]/body weight [kg] 1000);
b) SUV-max = the maximum pixel value measured in the
visualized lesion; c) SUV-mean = the average activity
values in the ROIs; d) TLG (Total Lesion Glycolysis) =
SUV-mean x metabolic tumor volume (mm3).
On the basis of these parameters, the following indica-
tor are calculated for each patients, in order to assess
metabolic response: 1) SUVmax = the highest SUVmax
value among all the evaluable lesions; 2) SUVmaxsum =
the sum of the SUVmax value of all the evaluable le-
sions; 3) TLGmax = the highest TLG value among all the
evaluable lesions; 4) TLGsum = the sum of the TLG
value of all the evaluable lesions.
Metabolic response is calculated by measuring changes
reported at the post treatment examination (at day11
after the start of the first cycle of chemotherapy in both
arms) compared to the baseline test. For all the indica-
tors the change is calculated as: Δ = (value-post – value-
baseline)/value-baseline × 100.
Consistent with previous studies [40–42] the threshold
to define a patient as responder according to change of
SUV or TLG indicators is ≥ 50 %. Therefore, patients with
any change above these thresholds are defined as non-
responder. This value will be validated within this study
for its predictive ability of survival outcome. Further
thresholds will be eventually explored only in case of fail-
ure (lack of predictive ability) of the proposed validation.
Biomarkers
Peripheral blood samples are collected at baseline, on
day 15th after the start of the first administration of bev-
acizumab in both arms (that is 11 days after the first
chemotherapy administration in the experimental arm)
at weeks 12 and 24, after randomization and at the pro-
gression of the disease (PD). Further blood samples are
collected before surgery in patients undergoing resection
of metastases. CEC and EPCs counts will be analyzed as
surrogate marker of tumor angiogenesis at baseline, on
day 15th after the start of the first administration of bev-
acizumab in both arms at weeks 12 and 24 and at PD,
by flow cytometry [30].
Analysis of polymorphisms in VEGF and VEGFR genes
will be evaluated on DNA from peripheral blood col-
lected at baseline and aliquoted and stored at −80 °C.
After DNA extraction the expression of the indicated
polymorphisms will be evaluated by RT-PCR using spe-
cific TAqman probes.
Analysis of circulating angiogenic factors and cyto-
kines will be performed on peripheral blood samples
aliquoted and stored at −80 °C (collected at each of the
above reported time-points for CEC and EPCs evaluation)
by Bio-Plex™ thecnology.
Analysis of miRNA will be performed on peripheral
blood samples aliquoted and stored at −80 °C (collected
at each of the above reported time-points for CEC and
EPCs evaluation) by droplet digital PCR (ddPCR) tech-
nology [44].
Analysis of cfDNA mutations will be performed on
peripheral blood samples aliquoted and stored at −80 °C
(collected at each of the above reported time-points for
CEC and EPCs evaluation and before metastasis sur-
gery). After genome equivalent absolute quantification
mutation analysisis will be performed by BEAMing,
Droplet digital PCR analysis or Next Generation Sequen-
cing analysis [45].
Finally we have planned to collect for a centralised
revision at the National Cancer Institute two tumor
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samples for all patients enrolled (primary tumor and
eventual resected metastases), to assess RAS and BRAF
mutations. We will also evaluate on collected tumor
samples other potential predictive markers of response.
Quality of life assessment
Quality of Life is assessed by the EORTC QLQ-C30, v.
3.0 questionnaire that are completed by patients at base-
line and at week 12 and 24 during treatment, in both
arms [46].
Statistical analysis
All analyses will be performed according to an intention
to treat strategy.
ORR is defined as the number of complete plus partial
response divided by the total of patients enrolled in each
comparison arm. ORR will be described by 2x2 contin-
gency tables and statistical significance of the possible
difference will be estimated by chi-square test. The dif-
ference between RR in the two arms will be estimated
with 95 % confidence interval.
Progression Free Survival (PFS) is defined as the time
from randomization to the date of progression, the date
of death without progression or the date of the last follow-
up information available, whichever occurred first. Curves
will be drawn with the Kaplan-Meier product-limit me-
thod. Statistical significance will be calculated by a model
of multivariable analysis considering stratification factors
as covariates.
Overall Survival (OS) is defined as the time from
randomization to the date of death or the date of ter-
mination of the trial (for patients alive at the time end of
the study), or the date of the last follow-up information
available (for patients loss before the trial end date).
Curves will be drawn with the Kaplan-Meier product-
limit method. Statistical significance will be calculated
by a model of multivariable analysis considering stratifi-
cation factors as covariates.
For each patient and type of toxicity, the worst degree
suffered during the treatment will be described. Patients
who will have not received assigned treatment will be
excluded. Statistical analysis will be performed by con-
tingency tables and statistical significance of the possible
differences between the treatment groups will be calcu-
lated with a linear permutation test accounting for or-
dinal nature of data (linear rank test).
Biomarkers data will be conducted with the aim of
hypothesis generation. First of all, a complete description
of data from biological and pharmacogenomic studies
will be done. For biomarkers that might change over
time as a consequence of treatment, levels before and
after treatment will be compared with appropriate statis-
tical tests, based on the type of data. P values ≤0.05 will
be considered significant, and no adjustment is planned
for multiple comparisons due to the exploratory nature
of the analysis.
Registration and data collection procedures
Procedures for registration, randomization and data
collection are centralized and web-based through the
on-line platform of the Clinical Trials Unit of the NCI of
Naples (http://www.usc-intnapoli.net.) Biological analyses
are centralized at the Experimental Pharmacology Unit of
the NCI of Naples. Randomization is performed with a
minimization procedure that accounts for the following
parameters as strata: center, ECOG performance status
(0 vs 1), previous chemotherapy for advanced disease
(yes vs no) and number of metastatic sites (1 vs more).
Discussion
The goal of OBELICS study is to evaluate the opti-
mization of bevacizumab scheduling in combination
with chemotherapy in mCRC patients by comparing in a
multicentre randomised phase 3 trial the traditional con-
comitant administration of bevacizumab in combination
with chemotherapy (mFOLFOX/OXXEL regimen), with
an experimental schedule, defined on the basis of “norma-
lization hypothesis”, in which bevacizumab is given 4 days
before chemotherapy.
Since there is an unmet need for pharmacodynamic
and predictive biomarkers of benefit for anti-angiogenic
drugs we will explore the potential predictive role of
several circulating biomarkers as well as of the early
metabolic response to improve the knowledge of the
mechanisms by which bevacizumab enhance chemother-
apy effect and to identify early predictors of response. In
particular, we plan to analyze, at multiple time points, a
complete kinetic profile of several potential biomarkers
on peripheral blood samples, considering that cancer
have a dynamic nature and that the possibility of evalu-
ating tumor changes by repeated biopsies is limited by
patients discomfort and tumor heterogeneity.
The SNPs of the VEGF gene, the count (baseline and
during treatment) of CECs and their progenitors EPCs,
together with a broad profile of cytokines and angiogenic
factors, could help to select the patients who are most
likely to benefit from these high-cost therapies and/or to
identify possible mechanisms of resistance. Multiplex
technologies offer a noninvasive, easy and convenient
method of simultaneously assessing a large number of
biologically relevant citochine and angiogenic factor
from small plasma volumes. Moreover, the high stability
of cfDNA and miRNA in the plasma of patients with
cancer and their correlation with the expression in the
tumor, suggest the possibility to identify innovative pre-
dictive biomarkers of benefit for anti-angiogenic therapy.
Pursuing imaging (FDG-PET) and circulating bio-
markers early after treatment initiation might be a fruitful
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approach, as many of the biomarker changes occur rapi-
dily after the onset of therapy and the ability to identify
these changes early may allow to tailor the therapy and to
discontinue early ineffective treatment.
Overall, the outcome of this correlative studies could
help to optimize anti-angiogenic therapy in CRC patients.
Trial sponsorship
The study is a multicentre non-profit, independent
investigator initiated trial supported by a grant of the
Ministry of Health (RF-2009-1539464). Istituto Nazionale
Tumori Fondazione G. Pascale, Napoli, Italy, will take out
insurance coverage for trial participants.
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